Matches in DBpedia 2016-04 for { ?s ?p "Talampanel (INN) (code names GYKI 537773, LY300164) is a drug which has been investigated for the treatment of epilepsy, malignant gliomas and amyotrophic lateral sclerosis (ALS).As of May 2010, results from the trial for ALS have been found negative. Talampanel is not currently under development.Talampanel acts as a non-competitive antagonist of the AMPA receptor, a type of glutamate receptor in the central nervous system."@en }
Showing triples 1 to 4 of
4
with 100 triples per page.
- Talampanel abstract "Talampanel (INN) (code names GYKI 537773, LY300164) is a drug which has been investigated for the treatment of epilepsy, malignant gliomas and amyotrophic lateral sclerosis (ALS).As of May 2010, results from the trial for ALS have been found negative. Talampanel is not currently under development.Talampanel acts as a non-competitive antagonist of the AMPA receptor, a type of glutamate receptor in the central nervous system.".
- Q7678869 abstract "Talampanel (INN) (code names GYKI 537773, LY300164) is a drug which has been investigated for the treatment of epilepsy, malignant gliomas and amyotrophic lateral sclerosis (ALS).As of May 2010, results from the trial for ALS have been found negative. Talampanel is not currently under development.Talampanel acts as a non-competitive antagonist of the AMPA receptor, a type of glutamate receptor in the central nervous system.".
- Talampanel comment "Talampanel (INN) (code names GYKI 537773, LY300164) is a drug which has been investigated for the treatment of epilepsy, malignant gliomas and amyotrophic lateral sclerosis (ALS).As of May 2010, results from the trial for ALS have been found negative. Talampanel is not currently under development.Talampanel acts as a non-competitive antagonist of the AMPA receptor, a type of glutamate receptor in the central nervous system.".
- Q7678869 comment "Talampanel (INN) (code names GYKI 537773, LY300164) is a drug which has been investigated for the treatment of epilepsy, malignant gliomas and amyotrophic lateral sclerosis (ALS).As of May 2010, results from the trial for ALS have been found negative. Talampanel is not currently under development.Talampanel acts as a non-competitive antagonist of the AMPA receptor, a type of glutamate receptor in the central nervous system.".